IMMP
Immutep Limited
Price Chart
Latest Quote
$3.15
+0.05 (+1.61%)
Current Price
| Previous Close | $3.10 |
| Open | $3.10 |
| Day High | $3.30 |
| Day Low | $3.10 |
| Volume | 13,557 |
Stock Information
Note: Financial values converted from AUD to USD
| Shares Outstanding | 7.37M |
| Total Debt | $736K |
| Cash Equivalents | $48.42M |
| Revenue | $14.01M |
| Net Income | $-55.75M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $23.21M |
| EPS (TTM) | $-7.30 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-44.61M |
| Sales | $14.01M |
| Income | $-55.75M |
| Book/sh | $5.90 |
| Cash/sh | $9.35 |
Financial Ratios
| Quick Ratio | 5.54 |
| Current Ratio | 5.69 |
| Debt/Eq | 1.70 |
Returns & Margins
| ROA | -42.45% |
| ROE | -77.31% |
| Operating Margin | -255.74% |
Ownership
| Insider Ownership | 0.01% |
| Institutional Ownership | 1.13% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.98 |
| P/S | 1.16 |
| P/B | 0.53 |
Analyst Data
| Recommendation | buy |
| Target Price | $30.00 |
Technical Indicators
| SMA20 | $3.65 |
| SMA50 | $5.54 |
| SMA200 | $17.84 |
| RSI | 16.79 |
| ATR | 0.2143 |
| Shares Float | 6.87M |
| Short Float | 1.35% |
| Short Ratio | 1.99 |
| Volatility | 2.30 |
| Rel Volume | 0.76 |
Performance History
| Week | -3.37% |
| Month | -35.45% |
| Quarter | -58.55% |
| 6 Months | -67.86% |
| YTD | -94.66% |
| Year | +54.41% |
| 3 Years | +54.41% |
| 5 Years | -26.91% |
| 10 Years | +11.18% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $3.15 | 13,557 |
| 2026-10-26 | $3.10 | 26,900 |
| 2026-10-23 | $3.20 | 7,900 |
| 2026-10-22 | $3.17 | 7,500 |
| 2026-10-21 | $3.28 | 9,200 |
| 2026-10-20 | $3.26 | 16,400 |
| 2026-10-19 | $3.17 | 6,800 |
| 2026-10-16 | $3.20 | 11,800 |
| 2026-10-15 | $3.21 | 19,000 |
| 2026-10-14 | $3.38 | 38,700 |
| 2026-10-13 | $3.57 | 27,000 |
| 2026-10-12 | $3.67 | 18,600 |
| 2026-10-09 | $3.63 | 23,400 |
| 2026-10-08 | $3.84 | 14,900 |
| 2026-10-07 | $4.06 | 9,600 |
| 2026-10-06 | $4.34 | 11,600 |
| 2026-10-05 | $4.27 | 25,200 |
| 2026-10-02 | $4.35 | 48,700 |
| 2026-10-01 | $4.54 | 11,000 |
| 2026-09-30 | $4.65 | 10,500 |
| 2026-09-29 | $4.71 | 34,000 |
| 2026-09-28 | $4.88 | 49,100 |
About Immutep Limited
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
đ° Latest News
No news articles available at the moment. Check back later for updates on IMMP.
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $10,115,999 | - | $0 | $0 |
| Operating Revenue | $10,115,999 | - | $0 | $0 |
| Expenses | ||||
| Interest Expense | $47,183 | - | $21,261 | $14,177 |
| Total Expenses | $66,816,588 | - | $32,354,039 | $28,791,734 |
| Other Income Expense | $-451,402 | - | $-7,871 | $428,325 |
| Other Non Operating Income Expenses | $-7,865 | - | $-86,716 | $-96,628 |
| Net Non Operating Interest Income Expense | $2,041,106 | - | $2,676,972 | $638,359 |
| Interest Expense Non Operating | $47,183 | - | $21,261 | $14,177 |
| Operating Expense | $66,816,588 | - | $32,354,039 | $28,791,734 |
| Other Operating Expenses | $-3,736,747 | - | $-2,669,824 | $-2,436,221 |
| General And Administrative Expense | $6,656,935 | - | $6,151,922 | $6,031,856 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-55,110,885 | - | $-29,684,938 | $-27,725,051 |
| Net Interest Income | $2,041,106 | - | $2,676,972 | $638,359 |
| Interest Income | $2,088,288 | - | $2,698,233 | $652,536 |
| Normalized Income | $-54,667,348 | - | $-29,763,783 | $-28,250,004 |
| Net Income From Continuing And Discontinued Operation | $-55,110,885 | - | $-29,684,938 | $-27,725,051 |
| Net Income Common Stockholders | $-55,110,885 | - | $-29,684,938 | $-27,725,051 |
| Net Income | $-55,110,885 | - | $-29,684,938 | $-27,725,051 |
| Net Income Including Noncontrolling Interests | $-55,110,885 | - | $-29,684,938 | $-27,725,051 |
| Net Income Continuous Operations | $-55,110,885 | - | $-29,684,938 | $-27,725,051 |
| Pretax Income | $-55,110,885 | - | $-29,684,938 | $-27,725,051 |
| Interest Income Non Operating | $2,088,288 | - | $2,698,233 | $652,536 |
| Operating Income | $-56,700,589 | - | $-32,354,039 | $-28,791,734 |
| Per Share | ||||
| Diluted EPS | $-0.37 | $-0.29 | $-0.25 | $-0.31 |
| Basic EPS | $-0.37 | $-0.29 | $-0.25 | $-0.31 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | - | $0 | $0 |
| Tax Rate For Calcs | $0 | - | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-54,620,165 | - | $-29,742,522 | $-28,235,827 |
| Total Unusual Items | $-443,537 | - | $78,845 | $524,953 |
| Total Unusual Items Excluding Goodwill | $-443,537 | - | $78,845 | $524,953 |
| EBITDA (Bullshit earnings) | $-55,063,702 | - | $-29,663,677 | $-27,710,874 |
| EBIT | $-55,063,702 | - | $-29,663,677 | $-27,710,874 |
| Diluted Average Shares | $102,263,813 | $101,168,760 | $83,465,041 | $62,015,276 |
| Basic Average Shares | $102,263,813 | $101,168,760 | $83,465,041 | $62,015,276 |
| Diluted NI Availto Com Stockholders | $-55,110,885 | - | $-29,684,938 | $-27,725,051 |
| Tax Provision | $0 | - | $0 | $0 |
| Gain On Sale Of Security | $-443,537 | - | $78,845 | $524,953 |
| Research And Development | $63,896,400 | - | $28,871,942 | $25,196,100 |
| Selling General And Administration | $6,656,935 | - | $6,151,922 | $6,031,856 |
| Other Gand A | $6,656,935 | - | $6,151,922 | $6,031,856 |
| Reconciled Depreciation | - | - | - | - |
Fetched: 2026-10-18
Balance Sheet (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $41,723,492 | - | $125,976,933 | $88,241,257 |
| Total Assets | $57,864,649 | - | $140,082,893 | $102,466,290 |
| Total Non Current Assets | $1,835,530 | - | $7,108,297 | $8,675,223 |
| Non Current Prepaid Assets | $35,495 | - | $909,089 | $1,754,629 |
| Goodwill And Other Intangible Assets | $1,037,485 | - | $5,726,850 | $6,595,012 |
| Other Intangible Assets | $961,070 | - | $5,650,434 | $6,518,596 |
| Current Assets | $56,029,119 | - | $132,974,596 | $93,791,067 |
| Hedging Assets Current | $0 | - | - | - |
| Prepaid Assets | $1,479,835 | - | $1,331,101 | $2,484,013 |
| Receivables | $6,687,543 | - | $5,252,628 | $5,540,746 |
| Other Receivables | $148,174 | $689,458 | $4,379,364 | $4,211,760 |
| Taxes Receivable | $6,386,572 | $6,852,626 | $869,621 | $1,238,175 |
| Accounts Receivable | $152,796 | - | $3,643 | $90,811 |
| Cash Cash Equivalents And Short Term Investments | $47,861,741 | - | $126,390,867 | $85,766,308 |
| Cash And Cash Equivalents | $44,247,782 | - | $112,432,348 | $85,766,308 |
| Cash Equivalents | $23,627,831 | - | $46,460,663 | $2,493,539 |
| Cash Financial | $20,619,951 | - | $65,971,685 | $83,272,769 |
| Restricted Cash | - | - | $0 | $0 |
| Accrued Interest Receivable | - | - | - | $14,644 |
| Debt | ||||
| Total Debt | $727,954 | - | $1,107,568 | $853,557 |
| Long Term Debt And Capital Lease Obligation | $526,322 | - | $945,220 | $724,853 |
| Current Debt And Capital Lease Obligation | $201,632 | - | $162,348 | $128,704 |
| Long Term Debt | - | - | $667,660 | $580,574 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,103,671 | - | $8,379,110 | $7,630,022 |
| Total Non Current Liabilities Net Minority Interest | $5,262,898 | - | $1,091,860 | $839,121 |
| Non Current Deferred Liabilities | $0 | - | $0 | $0 |
| Non Current Deferred Taxes Liabilities | $0 | - | $0 | $0 |
| Current Liabilities | $9,840,774 | - | $7,287,250 | $6,790,901 |
| Payables And Accrued Expenses | $9,319,973 | - | $6,645,007 | $6,271,439 |
| Payables | $4,306,712 | - | $2,931,844 | $4,032,701 |
| Other Payable | $215,732 | - | $297,921 | $246,590 |
| Accounts Payable | $4,090,981 | - | $2,633,924 | $3,786,111 |
| Derivative Product Liabilities | - | - | - | $0 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $42,760,978 | - | $131,703,783 | $94,836,269 |
| Total Equity Gross Minority Interest | $42,760,978 | - | $131,703,783 | $94,836,269 |
| Stockholders Equity | $42,760,978 | - | $131,703,783 | $94,836,269 |
| Gains Losses Not Affecting Retained Earnings | $24,098,168 | - | $20,892,086 | $20,936,566 |
| Retained Earnings | $-361,915,500 | - | $-265,911,856 | $-236,226,918 |
| Other | ||||
| Ordinary Shares Number | $1,024,128,785 | - | $1,009,459,559 | $832,710,765 |
| Share Issued | $1,024,128,785 | - | $1,009,459,559 | $832,710,765 |
| Tangible Book Value | $41,723,492 | - | $125,976,933 | $88,241,257 |
| Invested Capital | $42,760,978 | - | $132,371,443 | $95,416,843 |
| Working Capital | $46,188,345 | - | $125,687,347 | $87,000,166 |
| Capital Lease Obligations | $727,954 | - | $439,908 | $272,983 |
| Total Capitalization | $42,760,978 | - | $132,371,443 | $95,416,843 |
| Capital Stock | $380,578,309 | - | $376,723,553 | $310,126,621 |
| Common Stock | $380,578,309 | - | $376,723,553 | $310,126,621 |
| Employee Benefits | $227,139 | - | $141,194 | $114,268 |
| Non Current Accrued Expenses | $4,489,981 | $0 | - | - |
| Long Term Capital Lease Obligation | $526,322 | - | $277,560 | $144,279 |
| Long Term Provisions | $19,456 | - | $5,446 | - |
| Current Capital Lease Obligation | $201,632 | - | $162,348 | $128,704 |
| Pensionand Other Post Retirement Benefit Plans Current | $319,168 | - | $479,894 | $390,758 |
| Current Accrued Expenses | $5,013,261 | - | $3,713,163 | $2,238,738 |
| Goodwill | $76,416 | - | $76,416 | $76,416 |
| Net PPE | $762,550 | - | $472,358 | $325,582 |
| Accumulated Depreciation | $-544,967 | - | $-480,898 | $-448,024 |
| Gross PPE | $1,307,516 | - | $953,256 | $773,606 |
| Machinery Furniture Equipment | $621,831 | - | $524,779 | $505,803 |
| Buildings And Improvements | $685,685 | - | $428,477 | $267,803 |
| Properties | $0 | - | $0 | $0 |
| Other Short Term Investments | $3,613,958 | - | $13,958,519 | $0 |
Fetched: 2026-10-18
Cash Flow Statement (Annual)
| Metric | 2026-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-38,607,832 | $-24,846,142 | $-24,627,210 | $-21,023,396 |
| Operating Activities | ||||
| Cash Flowsfromusedin Operating Activities Direct | $-38,543,252 | $-24,198,214 | $-24,569,715 | $-21,007,472 |
| Other Cash Paymentsfrom Operating Activities | $-11,204,814 | - | - | - |
| Classesof Cash Receiptsfrom Operating Activities | $23,475,065 | $2,753,277 | $2,597,725 | $2,416,265 |
| Other Cash Receiptsfrom Operating Activities | $22,933 | $138,464 | $57,206 | $60,452 |
| Operating Cash Flow | - | - | - | $-30,538,142 |
| Cash Flow From Continuing Operating Activities | - | - | - | $-30,538,142 |
| Operating Gains Losses | - | - | - | $-336,169 |
| Investing Activities | ||||
| Capital Expenditure | $-64,580 | $-647,928 | $-57,495 | $-15,924 |
| Investing Cash Flow | $39,236,636 | $-14,606,447 | $-57,495 | $-15,924 |
| Cash Flow From Continuing Investing Activities | $39,236,636 | $-14,606,447 | $-57,495 | $-15,924 |
| Net Other Investing Changes | $-20,848 | - | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $-149,009 | $66,143,204 | $52,829,769 | $34,972,647 |
| Cash Flow From Continuing Financing Activities | $-149,009 | $66,143,204 | $52,829,769 | $34,972,647 |
| Issuance Of Capital Stock | - | $69,656,386 | $55,651,670 | $36,813,989 |
| Net Other Financing Charges | - | $-3,355,785 | $-2,674,594 | $-1,686,696 |
| Net Common Stock Issuance | - | $69,656,386 | $55,651,670 | $36,813,989 |
| Common Stock Issuance | - | $69,656,386 | $55,651,670 | $36,813,989 |
| Other | ||||
| Repayment Of Debt | $-149,009 | $-157,397 | $-147,306 | $-154,646 |
| End Cash Position | $44,247,782 | $112,432,348 | $85,766,308 | $55,590,778 |
| Beginning Cash Position | $46,843,791 | $85,766,308 | $55,590,778 | $42,107,847 |
| Effect Of Exchange Rate Changes | $-3,140,384 | $-672,504 | $1,972,972 | $-466,320 |
| Changes In Cash | $544,375 | $27,338,544 | $28,202,558 | $13,949,252 |
| Net Issuance Payments Of Debt | $-149,009 | $-157,397 | $-147,306 | $-154,646 |
| Net Long Term Debt Issuance | $-149,009 | $-157,397 | $-147,306 | $-154,646 |
| Long Term Debt Payments | $-149,009 | $-157,397 | $-147,306 | $-154,646 |
| Net Investment Purchase And Sale | $39,322,064 | $-13,958,519 | $0 | $0 |
| Sale Of Investment | $42,796,699 | - | - | - |
| Purchase Of Investment | $-3,474,635 | $-13,958,519 | $0 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-627,626 | $0 | $0 |
| Purchase Of Intangibles | $0 | $-627,626 | $0 | $0 |
| Net PPE Purchase And Sale | $-64,580 | $-20,302 | $-57,495 | $-15,924 |
| Purchase Of PPE | $-64,580 | $-20,302 | $-57,495 | $-15,924 |
| Interest Received Direct | $2,442,343 | $2,568,168 | $637,941 | $156,120 |
| Interest Paid Direct | $-28,202 | $-20,854 | $-14,274 | $-64,232 |
| Classesof Cash Payments | $-64,432,458 | $-29,498,804 | $-27,791,107 | $-23,515,625 |
| Paymentsto Suppliersfor Goodsand Services | $-53,227,644 | $-29,498,804 | $-27,791,107 | $-23,515,601 |
| Receiptsfrom Government Grants | $3,404,753 | $2,614,813 | $2,540,519 | $2,294,788 |
| Receiptsfrom Customers | $20,047,380 | $0 | $0 | $61,026 |
| Taxes Refund Paid Direct | - | $0 | $0 | $-24 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
| Change In Working Capital | - | - | - | $-1,577,118 |
| Change In Other Working Capital | - | - | - | $35,590 |
| Change In Other Current Assets | - | - | - | $-790,488 |
| Change In Payables And Accrued Expense | - | - | - | $1,450,103 |
| Change In Payable | - | - | - | $1,450,103 |
| Change In Receivables | - | - | - | $-2,272,323 |
| Other Non Cash Items | - | - | - | $328,049 |
| Stock Based Compensation | - | - | - | $1,502,009 |
| Depreciation Amortization Depletion | - | - | - | $2,084,512 |
| Depreciation And Amortization | - | - | - | $2,084,512 |
| Gain Loss On Investment Securities | - | - | - | $-597,100 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | $260,931 |
| Net Income From Continuing Operations | - | - | - | $-32,539,426 |
Fetched: 2026-10-18